Regulation of tumour drug delivery by blood flow chronobiology

European Journal of Cancer

Volumn 36, Issue 14, 2000, Pages 1876-1884

  Blumenthal, R D ^a   Osorio, L ^a   Ochakovskaya, R ^a   Ying, Z ^b   Goldenberg, D M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMOTHERAPY; CHRONOBIOLOGY; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; MALE; MOUSE; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; TUMOR BLOOD FLOW; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD FLOW VELOCITY; CAPILLARY PERMEABILITY; CHRONOBIOLOGY; COLONIC NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033900368     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00177-5     Document Type: Article

References (47)

1. Skarsgard L.D., Vinczan A., Skwarchuk M.W., Chaplin D.J. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;363-367.
2. Jain R.K. Determinants of tumor blood flow. a review Cancer Res. 48:1988;2641-2658.
3. Chaplin D.J., Hill S.A., Bell K.M., Tozer G.M. Modification of tumor blood flow. current status and future directions Semin. Radiat. Oncol. 8:1998;151-163.
4. Sands H., Jones P., Shah S., Palme D., Vessella R., Gallagher B. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clousner and Renal Cell xenografts. Cancer Res. 48:1988;188-193.
5. Bomber P., McCreedy R., Hambersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake following gallium-67 in a mouse sarcoma. J. Nucl. Med. 27:1986;243-245.
6. Suzuki M., Hori K., Abe I., Saito S., Sato H. A new approach to cancer chemotherapy. selective enhancement of tumor blood flow with angiotensin II J. Natl. Cancer Inst. 67:1981;663-669.
7. Zhou S., Wang N., Liu T., Dong Z. Experimental study of tumor directed therapy with gastric cancer monoclonal antibody-mitomycin conjugate combined with propranolol or angiotensin II. Acta Pharm. Sinica. 27:1992;891-894.
8. Smyth M., Pietersz G., McKenzie I. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J. Natl. Cancer Inst. 79:1987;1367-1373.
9. Pimm M. An examination of the influence of vasoactive drugs on blood flow and localisation of a monoclonal antibody in human tumor xenografts. Br. J. Cancer. 62:1990;69-71.
10. Blumenthal R.D., Sharkey R.M., Kashi R., Natale A.M., Goldenberg D.M. Physiological factors influencing radioantibody uptake. a study of four human colonic carcinomas Int. J. Cancer. 51:1992;935-941.
11. Blumenthal R.D., Sharkey R.M., Kashi R., Natale A.M., Goldenberg D.M. Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft. Int. J. Cancer. 44:1989;1041-1047.
12. Hori K., Suzuki M., Tanda S., Saito S., Shinozaki M., Zhang Q. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-indirected hypertension. Cancer Res. 52:1992;912-916.
13. Smaaland R., Laerum O.D., Abrahamsen J.F., Sothern R.B., Lote K. Cytokinetic circadian patterns in human host and tumor. J. Infus. Chemother. 5:1995;11-14.
14. Hrushesky W.J. Cancer chronotherapy. a drug delivery challenge Prog. Clin. Biol. Res. 341:1990;1-10.
15. Hori K., Zhang Q., Li H., Saito S., Sato Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int. J. Cancer. 65:1996;360-364.
16. Hori K., Zhang Q., Saito S. Variation of growth rate of a rat tumour during a light-dark cycle. correlation with circadian fluctuations in tumour blood flow Br. J. Cancer. 71:1995;1163-1168.
17. Goldenberg D.M., Witte S., Elster K. A new human tumor serially transplantable in the golden hamster. Transplantation. 4:1967;760-766.
18. Zanelli G., Lucas P., Fowler J. The effect of anesthesia on blood perfusion in transplanted mouse tumors. Br. J. Cancer. 32:1975;380-389.
19. Saperstein L. Regional blood flow by fractional distribution of indicators. Am. J. Physiol. 193:1958;161-168.
20. Zar J. One-sample Hypotheses. Biostatistical Analysis. 1974;Prentice Hall, Inc, Englewood Cliffs, NJ. 86-100.
21. Halberg F., Johnson E., Nelson W., Runge W., Sothern R. Autorhythmometry procedures for physioloic self-measurements and their analysis. Phys. Teacher. 1:1972;1-11.
22. Nelson W., Tong Y., Lee J., Halberg F. Methods for cosinor rhythmometry. Chronobiologica. 6:1979;866.
23. Sharkey R.M., Juweid M., Shevitz H.J.et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res. 55:1995;5935-5945.
24. Blumenthal R.D., Sharkey R.M., Kashi R., Sides K.R.S., Goldenberg D.M. Changes in tumor vascular permeability in response to experimenal radioimmunothrapy. a comparitive study of 11 xenografts Tumor Biol. 18:1997;367-377.
25. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 46:1986;467-473.
26. Collins P., Connolly D., Williams T. Characterization of the increase in vascular permeability factor in vivo. Br. J. Pharmacol. 109:1993;195-199.
27. Roberts W., Hasan T. Tumor secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake. Cancer Res. 53:1993;153-157.
28. Terman B.I., Dougher-Vermazen M., Carrion M.E.et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
29. de Vries C., Escobedo J., Ueno H., Houck K., Ferrara N., Williams L. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
30. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56:1996;2013-2016.
31. Brown L.F., Berse B., Jackman R.W.et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143:1993;1255-1262.
32. Jenkins D., Charles I., Baylis S., Lelchuk R., Radomski M. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br. J. Cancer. 70:1994;847-849.
33. Chan R., Babbs C., Vetter R., Lamar C. Abnormal response to tumor vasculature to vasoactive drugs. J. Natl. Cancer Inst. 72:1984;145-150.
34. Mattsson J., Lilja J., Peterson H. Influence of vasoactive drugs on local tumor blood flow. Eur. J. Cancer. 18A:1982;677-684.
35. Noguchi S., Miyauchi K., Nishizawa Y.et al. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy with breast carcinoma. Cancer. 62:1988;467-473.
36. Braunschweiger P., Schiffer L. Effect of dexamethasone on vascular function in RIF-1 tumors. Cancer Res. 46:1986;3299-3303.
37. Jirtle R. Cheminal modification of tumor blood flow. Int. J. Hyperthermia. 4:1988;355-371.
38. Tozer G., Shaffi K. Modification of tumor blood flow using the hypertensive agents, angiotensin II. Br. J. Cancer. 67:1993;981-988.
39. Kallinowski F., Schlenger K.H., Kloes M., Stohrer M., Vaupel P. Tumor blood flow. the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo Int. J. Cancer. 44:1989;266-272.
40. Solesvik O., Rofstad E., Brustad T. Vascular structure of five human malignant melanomas grown in athymic nude mice. Br. J. Cancer. 46:1982;557-567.
41. Grunt T., Lametschwandtner A., Staindl O. The vascular pattern of basal cell tumors. light microscopy and scanning electron microscopic study on vascular corrosion casts Microvasc. Res. 29:1985;371-386.
42. Rubin P., Casarett G. Microcirculation of tumors. I. Anatomy, function and necrosis. Clin. Radiol. 17:1966;220-229.
43. Li P., Sur S.H., Mistlberger R.E., Morris M. Circadian blood pressure and heart rate rhythms in mice. Am. J. Physiol. 276:1999;R500.
44. Naguib F., Soong S., el Kouni M. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem. Pharmacol. 45:1993;667-673.
45. Harris B., Song R., Soong S., Diasio R. Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res. 49:1989;6610-6614.
46. Levi F. Chronopharmacology and chronotherapy of cancers. Path. Biol. 44:1996;631-644.
47. Blumenthal R., Reising A., Lew W., Dunn R., Ying Z., Goldenberg D. Chronotolerance of experimental radioimmunotherapy. clearance, toxicity and maximal tolerated dose of I-131-anti-CEA IgG as a function of time of day of dosing in a murine model Eur. J. Cancer. 35:1999;815-824.